Replies to post #114333 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

BOMC That is consistent with Missling's statement of optimizing the chances of success.

Dado's post did lead me to contemplate that the three trials results can be combined to demonstrate a much broader applicability of 2-73.

If the selections of subjects based on genomics and bio markers are sufficiently different in each trial, then when combined, there is larger overall suitable population for 2-73. Perhaps enough to make it a general application drug.

Just contemplating.